CSF2 and neurodegenerative disease: Moreover, administration of GM-CSF or other agents that induce tolerogenic DCs leading to increases in numbers of Tregs and Treg activity, present an attractive therapeutic strategy for decreasing neuroinflammation in autoimmune or neurodegenerative diseases.